Vivera Prevails in Litigation Against Former Los Angeles Commissioner Pedram Salimpour
NEWPORT BEACH, Calif.—Vivera Pharmaceuticals, Inc. is pleased to announce the litigation involving Pedram Salimpour has been dismissed, leaving Salimpour with nothing by way of settlement.
Vivera Refiles $500 Million Lawsuit Against USA Today With Newly Discovered Information
NEWPORT BEACH, Calif.— Vivera Pharmaceuticals, Inc. announces the re-filing of its defamation lawsuit against USA Today and parent companies Gannett Co., Inc. and Gannett Satellite Information
Vivera Pharmaceuticals Secures United Kingdom Patent for Innovative ZICOH Smart Inhaler Device
NEWPORT BEACH, Calif. — Vivera, a science-driven biopharma and medtech company, is pleased to announce that the U.K. Intellectual Property Office (IPO) has granted the Company’s ZICOH
Vivera Secures Patent for Innovative Speech Fluency Evaluation and Feedback Device
NEWPORT BEACH, Calif. — Vivera is proud to announce that it has received a patent for its groundbreaking Speech Fluency Evaluation and Feedback Monitoring Device from
Vivera Welcomes Former FDA Investigator Dennis Moore as Regulatory and Compliance Advisor
NEWPORT BEACH, Calif. – Vivera welcomes Mr. Dennis Moore as its Regulatory and Compliance Advisor. Mr. Moore will guide Vivera through the regulatory pathway for
Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent
NEWPORT BEACH, Calif. — With its exclusive global license to the TABMELT technology for pharmaceutical use, Vivera is pleased to announce the expansion of the
Investor Relations and Media Inquiries:
Investor Inquiries:
[email protected]
Media Inquiries:
[email protected]
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.
